Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

22.72
+0.89004.08%
Post-market: 22.720.00000.00%19:20 EST
Volume:2.13M
Turnover:47.99M
Market Cap:2.19B
PE:-3.90
High:22.87
Open:21.56
Low:21.31
Close:21.83
52wk High:45.00
52wk Low:18.41
Shares:96.48M
Float Shares:92.79M
Volume Ratio:0.64
T/O Rate:2.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8316
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-22.03%
PB:-27.40
PE(LYR):-3.90

Loading ...

Rosen Law Firm Urges Ultragenyx Investors to Act Before April 6 Lead Plaintiff Deadline

Reuters
·
Feb 21

Ultragenyx Grants 22,917 RSUs to Six Newly Hired Officers Under Inducement Plan

Reuters
·
Feb 21

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 21

Schall Law Firm Files Securities Fraud Class Action Against Ultragenyx Pharmaceutical Inc

Reuters
·
Feb 21

Levi & Korsinsky Files Securities Class Action Against Ultragenyx Pharmaceutical Inc

Reuters
·
Feb 20

Ultragenyx Faces Securities Class Action as Lead Plaintiff Deadline Nears

Reuters
·
Feb 19

Ultragenyx FY 2025 Evkeeza product sales jump to USD 59 million (+84%)

Reuters
·
Feb 19

Ultragenyx Lawsuits Add Legal Overhang To Setrusumab Setback And 2027 Goals

Simply Wall St.
·
Feb 19

Ultragenyx Pharma Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Feb 18

Ultragenyx Faces Securities Class Action After Stock Plunge

Reuters
·
Feb 18

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Feb 17

Ultragenyx price target lowered to $37 from $39 at Evercore ISI

TIPRANKS
·
Feb 17

Ultragenyx Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Feb 17

Ultragenyx price target lowered to $50 from $60 at H.C. Wainwright

TIPRANKS
·
Feb 17

Ultragenyx Faces Securities Class Action Over Misleading Study Claims

Reuters
·
Feb 16

Is Ultragenyx Pharmaceutical (RARE) Mispriced After Steep Multi‑Year Share Price Declines?

Simply Wall St.
·
Feb 16

Ultragenyx Faces Securities Class Action Over Alleged Misleading Statements

Reuters
·
Feb 15

Ultragenyx Faces Class Action Lawsuit Over Alleged Misleading Statements on Setrusumab Trials

Reuters
·
Feb 14

Why Is Ultragenyx Stock Sinking Friday?

Benzinga
·
Feb 14

Ultragenyx Pharmaceutical Faces Lawsuit Following Clinical Trial Disclosures

TIPRANKS
·
Feb 14